PE20010964A1 - Derivados de tiazolilamida - Google Patents
Derivados de tiazolilamidaInfo
- Publication number
- PE20010964A1 PE20010964A1 PE2000001387A PE0013872000A PE20010964A1 PE 20010964 A1 PE20010964 A1 PE 20010964A1 PE 2000001387 A PE2000001387 A PE 2000001387A PE 0013872000 A PE0013872000 A PE 0013872000A PE 20010964 A1 PE20010964 A1 PE 20010964A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- derivatives
- cycloalkyl
- halogen
- alcoxy
- Prior art date
Links
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 abstract 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
- 241001529453 unidentified herpesvirus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A DERIVADOS DE TIAZOLILAMIDA DE FORMULA I DONDE R1 ES H, HALOGENO, ALQUILO C1-C6, ALCOXI C1-C6, AMINOALQUILO C1-C6, HALOGENOALQUILO C1-C6; R2 Y R3 SON H, ALCOXI C1-C6, CICLOALQUILO C3-C8, BIFENILAMINOCARBONILO, ALQUILO C1-C6, -P(=O)(OR9)(OR8); C=OCH(NH2)(R10), -C(R11)(H)(O-COR12), CH(R10')(NH2); R8 Y R9 SON H, ALQUILO C1-C4; R10 Y R10' SON O-AMINOACIDO; R11 ES ALQUILO C1-C4, R12 ES H, ALQUILO C1-C4; R2 Y R3 JUNTO A N FORMAN UN HETEROCICLO DE 5-6 MIEMBROS; R4 ES H, ACILO C1-C6, ALQUENILO C2-C6, CICLOALQUILO C3-C8; R4 ES H, ACILO C1-C6, ALQUENILO C1-C6, CICLOALQUILO C3-C8, ENTRE OTROS; R5 Y R7 SON H, ALQUILO C1-C6, HALOGENO, AMINO, DIALQUILAMINO C1-C6, ENTRE OTROS; R6 ES FENILO OPCIONALMENTE SUSTITUIDO CON HALOGENO, ARILO C6-C10, ALQUILTIO C1-C6, ENTRE OTROS; UN COMPUESTO PREFERIDO DE FORMULA II. TAMBIEN SE REFIERE AL USO DE DERIVADOS DE N-[5-(AMINOSULFONIL)-1,3-TIAZOL-2-IL]ACETAMIDA. EL COMPUESTO I PUEDE SER UTIL PARA EL TRATAMIENTO DE INFECCIONES VIRICAS POR HERPESVIRUS, HERPES SIMPLE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19962532A DE19962532A1 (de) | 1999-12-23 | 1999-12-23 | Thiazolylamid-Derivate |
| DE10039265A DE10039265A1 (de) | 2000-08-11 | 2000-08-11 | Thiazolylamid-Derivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010964A1 true PE20010964A1 (es) | 2001-11-10 |
Family
ID=26006669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000001387A PE20010964A1 (es) | 1999-12-23 | 2000-12-22 | Derivados de tiazolilamida |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7105553B2 (es) |
| EP (1) | EP1244641B1 (es) |
| JP (1) | JP4726175B2 (es) |
| KR (1) | KR100768361B1 (es) |
| CN (1) | CN1235890C (es) |
| AR (1) | AR029210A1 (es) |
| AT (1) | ATE293104T1 (es) |
| AU (1) | AU784286B2 (es) |
| BR (1) | BR0017030B8 (es) |
| CA (1) | CA2396720C (es) |
| CO (1) | CO5261491A1 (es) |
| DE (1) | DE50010060D1 (es) |
| DK (1) | DK1244641T3 (es) |
| DO (1) | DOP2000000109A (es) |
| ES (1) | ES2240233T3 (es) |
| HK (1) | HK1057552A1 (es) |
| IL (2) | IL149897A0 (es) |
| MX (1) | MXPA02006243A (es) |
| MY (1) | MY134880A (es) |
| NZ (1) | NZ519701A (es) |
| PE (1) | PE20010964A1 (es) |
| PL (1) | PL208707B1 (es) |
| PT (1) | PT1244641E (es) |
| SV (1) | SV2002000249A (es) |
| TW (1) | TWI256951B (es) |
| UY (1) | UY26495A1 (es) |
| WO (1) | WO2001047904A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1319185A1 (en) * | 2000-06-15 | 2003-06-18 | Bayer Aktiengesellschaft | Method for identifying compounds with anti-herpes activity |
| DE10129714A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Topische Anwendung von Thiazolylamiden |
| DE10131128A1 (de) * | 2001-06-28 | 2003-01-16 | Bayer Ag | Sekundäre Sulfonamide |
| AR036873A1 (es) | 2001-09-07 | 2004-10-13 | Euro Celtique Sa | Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento |
| AR037233A1 (es) | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
| DE602005024827D1 (de) * | 2004-09-09 | 2010-12-30 | Novartis Vaccines & Diagnostic | Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen |
| DE102005014248A1 (de) * | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid |
| WO2007037898A2 (en) * | 2005-08-29 | 2007-04-05 | Housey Pharmaceuticals Inc | Theramutein modulators |
| EP2029138A1 (en) * | 2005-06-03 | 2009-03-04 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| WO2007019397A2 (en) * | 2005-08-05 | 2007-02-15 | Genelabs Technologies, Inc. | 6-membered aryl and heteroaryl derivatives for the treatment of hepatitis c virus |
| EP3124471B1 (en) * | 2006-03-17 | 2020-06-03 | The Johns Hopkins University | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors |
| WO2008140583A2 (en) * | 2006-11-22 | 2008-11-20 | The Regents Of The University Of California | Functionalized boron nitride nanotubes |
| EP2573086A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
| EP2573085A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| US20150374676A1 (en) * | 2013-02-12 | 2015-12-31 | Aicuris Gmbh & Co. Kg | Helicase-primase inhibitors for use in a method of treating alzheimer's disease |
| SG11201700061PA (en) * | 2014-07-07 | 2017-02-27 | Prophylaxis LLC | Viral prophylaxis treatment methods and pre-exposure prophylaxis kits |
| EP3440063B1 (en) * | 2016-04-06 | 2020-08-05 | Innovative Molecules GmbH | Aminothiazole derivatives useful as antiviral agents |
| CN110062755B (zh) | 2016-11-28 | 2023-08-29 | 艾库里斯有限及两合公司 | 普瑞利韦的游离碱的马来酸盐、其药物制剂、其制造方法及其用于治疗疱疹病毒的用途 |
| RS61905B1 (sr) | 2016-11-28 | 2021-06-30 | Aicuris Gmbh & Co Kg | Hemihidrat slobodne baze n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida, postupci njegove proizvodnje i upotrebe |
| AR110250A1 (es) | 2016-11-28 | 2019-03-13 | Aicuris Anti Infective Cures Gmbh | Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida |
| CN110225781B (zh) * | 2017-01-09 | 2022-05-17 | 辉诺生物医药科技（杭州）有限公司 | 噻唑衍生物及其应用 |
| CN111433203B (zh) | 2017-10-05 | 2024-02-13 | 创新分子股份有限公司 | 作为抗病毒化合物的取代噻唑的对映异构体 |
| KR102535452B1 (ko) | 2018-07-06 | 2023-05-26 | 파에노 테라퓨틱스 씨오., 엘티디. | 티아졸 화합물의 결정형 및 이의 응용 |
| EP3925595A1 (en) | 2020-06-17 | 2021-12-22 | AiCuris GmbH & Co. KG | Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl] acetamide hemihydrate |
| KR20220160024A (ko) | 2020-03-26 | 2022-12-05 | 아이쿠리스 게엠베하 운트 코. 카게 | N-[5-(아미노술포닐)-4-메틸-1,3-티아졸-2-일]-n-메틸-2-[4-(2-피리디닐)페닐]아세트아미드 반수화물을 포함하는 안과용 제제 |
| JP2023552274A (ja) | 2020-10-29 | 2023-12-15 | イノベーティブ モレキュールズ ゲーエムベーハー | 抗ウイルス化合物としての重水素化アミノチアゾール化合物 |
| WO2023135303A1 (en) | 2022-01-17 | 2023-07-20 | Innovative Molecules Gmbh | Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof |
| WO2024049760A1 (en) | 2022-08-29 | 2024-03-07 | Assembly Biosciences, Inc. | Cyclic urea thiazolyl compounds for treatment of hsv |
| WO2024047507A1 (en) | 2022-08-29 | 2024-03-07 | Assembly Biosciences, Inc. | A novel crystalline form of pritelivir |
| WO2024047508A1 (en) | 2022-08-29 | 2024-03-07 | Assembly Biosciences, Inc. | Pharmaceutical compositions for herpes virus |
| WO2024047506A1 (en) | 2022-08-29 | 2024-03-07 | Assembly Biosciences, Inc. | A novel crystalline form of pritelivir |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3658830A (en) | 1970-01-16 | 1972-04-25 | Shell Oil Co | 5-(substituted mercapto sulfiny sulfonyl or sulfamoyl) |
| CH564301A5 (es) | 1970-01-16 | 1975-07-31 | Shell Int Research | |
| US3847588A (en) | 1970-04-20 | 1974-11-12 | Shell Oil Co | Thiazoles herbicidal |
| US3717651A (en) | 1970-04-20 | 1973-02-20 | Shell Oil Co | Thiazoles |
| WO1997024343A1 (en) * | 1995-12-29 | 1997-07-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Phenyl thiazole derivatives with anti herpes virus properties |
| GB2311068A (en) | 1996-03-14 | 1997-09-17 | Merck & Co Inc | Helicase isolated from human cytomegalovirus (HCMV) |
| GB2311069A (en) | 1996-03-14 | 1997-09-17 | Merck & Co Inc | Primase isolated from human cytomegalovirus (HCMV) |
| US5705344A (en) | 1996-03-14 | 1998-01-06 | Tularik, Inc. | High-throughput screening assay for inhibitors of nucleic acid helicases |
| CA2223032A1 (en) | 1997-02-21 | 1998-08-21 | Smithkline Beecham Corporation | Use of hsv-1 ul-15 and vp5 in identifying anti-viral agents |
| DE19802437A1 (de) | 1998-01-23 | 1999-07-29 | Bayer Ag | Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe |
| AU3289299A (en) | 1998-02-19 | 1999-09-06 | Tularik Inc. | Antiviral agents |
| ATE229945T1 (de) | 1998-03-19 | 2003-01-15 | Upjohn Co | Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole |
| US6500817B1 (en) | 1999-03-08 | 2002-12-31 | Bayer Aktiengesellschaft | Thiazolyl urea derivatives and their utilization as antiviral agents |
-
2000
- 2000-12-05 DO DO2000000109A patent/DOP2000000109A/es unknown
- 2000-12-12 KR KR1020027008155A patent/KR100768361B1/ko active IP Right Grant
- 2000-12-12 ES ES00991169T patent/ES2240233T3/es not_active Expired - Lifetime
- 2000-12-12 JP JP2001549375A patent/JP4726175B2/ja not_active Expired - Lifetime
- 2000-12-12 AT AT00991169T patent/ATE293104T1/de active
- 2000-12-12 CN CNB008189676A patent/CN1235890C/zh not_active Expired - Lifetime
- 2000-12-12 EP EP00991169A patent/EP1244641B1/de not_active Expired - Lifetime
- 2000-12-12 IL IL14989700A patent/IL149897A0/xx active IP Right Grant
- 2000-12-12 MX MXPA02006243A patent/MXPA02006243A/es active IP Right Grant
- 2000-12-12 DE DE50010060T patent/DE50010060D1/de not_active Expired - Lifetime
- 2000-12-12 PL PL356484A patent/PL208707B1/pl unknown
- 2000-12-12 PT PT00991169T patent/PT1244641E/pt unknown
- 2000-12-12 NZ NZ519701A patent/NZ519701A/en not_active IP Right Cessation
- 2000-12-12 CA CA002396720A patent/CA2396720C/en not_active Expired - Lifetime
- 2000-12-12 AU AU31574/01A patent/AU784286B2/en not_active Expired
- 2000-12-12 BR BRPI0017030A patent/BR0017030B8/pt not_active IP Right Cessation
- 2000-12-12 WO PCT/EP2000/012564 patent/WO2001047904A1/de active IP Right Grant
- 2000-12-12 DK DK00991169T patent/DK1244641T3/da active
- 2000-12-12 US US10/168,197 patent/US7105553B2/en not_active Expired - Lifetime
- 2000-12-20 UY UY26495A patent/UY26495A1/es not_active Application Discontinuation
- 2000-12-20 AR ARP000106789A patent/AR029210A1/es active IP Right Grant
- 2000-12-21 MY MYPI20006089A patent/MY134880A/en unknown
- 2000-12-22 TW TW089127599A patent/TWI256951B/zh not_active IP Right Cessation
- 2000-12-22 PE PE2000001387A patent/PE20010964A1/es not_active IP Right Cessation
- 2000-12-22 SV SV2000000249A patent/SV2002000249A/es active IP Right Grant
- 2000-12-22 CO CO00097414A patent/CO5261491A1/es active IP Right Grant
-
2002
- 2002-05-28 IL IL149897A patent/IL149897A/en unknown
-
2004
- 2004-01-19 HK HK04100401A patent/HK1057552A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20010964A1 (es) | Derivados de tiazolilamida | |
| AR035548A1 (es) | Compuestos organicos | |
| AR040031A1 (es) | Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen | |
| PE20051057A1 (es) | Fenilalanina-amidas sustituidas por heteroaroilo | |
| PE20051039A1 (es) | [1,8] naftiridin-2-onas y compuestos relacionados | |
| ES2141137T3 (es) | Agentes terapeuticos para la enfermedad de parkinson. | |
| CY1105688T1 (el) | Κυανοπυρρολες ως αγωνιστες υποδοχεων προγεστερονης | |
| PE20050420A1 (es) | Fenacilo 2-hidroxi-3-diaminoalcanos | |
| PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
| KR950014097A (ko) | 피페라진 유도체 | |
| PE20040155A1 (es) | Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen | |
| PE20050482A1 (es) | Derivados de dihidrobenzofuranilo alcanamida | |
| RU2008131051A (ru) | Избирательное n-сульфонилирование 2-амино трифторалкильнзамещенных спиртов | |
| PE20030137A1 (es) | Derivados antimicrobianos de quinolona | |
| PE20090477A1 (es) | Derivados de oxazol como inhibidores de los canales de sodio | |
| PE20010741A1 (es) | Derivados de piperazina como antagonistas de taquicininas | |
| AR038881A1 (es) | Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un procedimiento para la preparcion de aquellos | |
| PE20011089A1 (es) | Tioamidas de oxazolidinona con sustituyentes de piperazin-amida | |
| ES2578302T3 (es) | Compuestos de 5,6-dihidro-1H-piridin-2-ona | |
| NO952208D0 (no) | Amin-derivater | |
| DE60137540D1 (de) | Methoden zur behandlung von angstzuständen | |
| EP1176958A4 (en) | NEW CATECHOLS USED AS ANTIMICROBIAL AGENTS | |
| PE20020253A1 (es) | Derivados de 3-azabiciclo[3.1.0]hexano como ligandos de receptores opiaceos | |
| PE20020189A1 (es) | Oxazinquinolonas utiles en el tratamiento de infecciones virales | |
| PE20021061A1 (es) | Arilsulfonamidas como agentes antivirales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| MK | Expiration of term |